179 related articles for article (PubMed ID: 65817)
41. [Magnetic resonance tomography of prostatic cancer. A histopathologic correlation].
Kahn T; Bürrig KF; Schmitz-Dräger B; Fürst G; Stork W; Mödder U
Radiologe; 1989 Mar; 29(3):144-9. PubMed ID: 2469100
[TBL] [Abstract][Full Text] [Related]
42. [Clinico-morphological characteristics of latent form of prostatic cancer].
Kliucharev BV; Vorob'ev AV
Vestn Khir Im I I Grek; 1979 May; 122(5):45-9. PubMed ID: 88120
[TBL] [Abstract][Full Text] [Related]
43. [Low-stage prostatic adenocarcinoma and atypical lesions of the prostate].
Maganto Pavón E; García González R; Ruiz Zárate C; Fernández González I; Fernández Fernández A; Vallejo Herrador J; Mateos Torres A; Escudero Barrilero A
Arch Esp Urol; 1990; 43(9):967-70. PubMed ID: 1708979
[TBL] [Abstract][Full Text] [Related]
44. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
Semjonow A; Hamm M; Rathert P
Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557
[TBL] [Abstract][Full Text] [Related]
45. Lack of value of radioimmunoassay for prostatic acid phosphatase as a screening test for prostatic cancer in patients with obstructive prostatic hyperplasia.
Fleischmann J; Catalona WJ; Fair WR; Heston WD; Menon M
J Urol; 1983 Feb; 129(2):312-4. PubMed ID: 6187945
[TBL] [Abstract][Full Text] [Related]
46. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
47. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
Urologiia; 2001; (2):37-40. PubMed ID: 11490716
[TBL] [Abstract][Full Text] [Related]
48. Pitfalls in the diagnosis of prostate adenocarcinoma from holmium resection of the prostate.
Gan E; Costello A; Slavin J; Stillwell RG
Tech Urol; 2000 Sep; 6(3):185-8. PubMed ID: 10963483
[TBL] [Abstract][Full Text] [Related]
49. Common misconceptions about the prostate gland.
Greene LF
Am Fam Physician; 1974 Sep; 10(3):80-5. PubMed ID: 4137583
[No Abstract] [Full Text] [Related]
50. [Frequency and differential diagnosis of cribriform structures of the prostate].
Mehlhorn J
Zentralbl Pathol; 1991; 137(4):349-54. PubMed ID: 1722706
[TBL] [Abstract][Full Text] [Related]
51. Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making.
Nnabugwu II; Ugwumba FO; Enivwenae OA; Udeh EI; Otene CO; Nnabugwu CA
Clin Interv Aging; 2015; 10():89-93. PubMed ID: 25565791
[TBL] [Abstract][Full Text] [Related]
52. [Occult cancer in patients with symptomatic benign prostatic hyperplasia].
Rodríguez Duarte C; Aguillón J; Rodríguez H
Arch Esp Urol; 1991 May; 44(4):411-4. PubMed ID: 1712190
[TBL] [Abstract][Full Text] [Related]
53. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
[TBL] [Abstract][Full Text] [Related]
54. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
[TBL] [Abstract][Full Text] [Related]
55. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
56. Malakoplakia associated with prostatic adenocarcinoma: Report of 4 cases and literature review.
Medlicott S; Magi-Galluzzi C; Jimenez RE; Trpkov K
Ann Diagn Pathol; 2016 Jun; 22():33-7. PubMed ID: 27180057
[TBL] [Abstract][Full Text] [Related]
57. Management of a giant prostatic enlargement: Case report and review of the literature.
Ojewola RW; Tijani KH; Fatuga AL; Onyeze CI; Okeke CJ
Niger Postgrad Med J; 2020; 27(3):242-247. PubMed ID: 32687126
[TBL] [Abstract][Full Text] [Related]
58. [A case of prostate cancer diagnosed one and half year after retropubic prostatectomy for benign prostatic hypertrophy].
Kato Y; Nakata S; Sato J; Mayuzumi T; Shimizu T
Hinyokika Kiyo; 1996 Nov; 42(11):907-9. PubMed ID: 8973946
[TBL] [Abstract][Full Text] [Related]
59. Cytological atypia in the prostate gland: frequency, distribution and possible relevance to carcinoma.
Oyasu R; Bahnson RR; Nowels K; Garnett JE
J Urol; 1986 May; 135(5):959-62. PubMed ID: 2421020
[TBL] [Abstract][Full Text] [Related]
60. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma.
Tomas D; Kruslin B
Prostate; 2004 Dec; 61(4):324-31. PubMed ID: 15389817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
